Teladoc Total Liab from 2010 to 2024

TDOC Stock  USD 10.40  1.40  15.56%   
Teladoc's Total Liabilities is increasing over the years with slightly volatile fluctuation. Overall, Total Liabilities is expected to go to about 2.2 B this year. Total Liabilities is the total amount of all liabilities that Teladoc has, including both short-term and long-term liabilities. View All Fundamentals
 
Total Liabilities  
First Reported
2013-12-31
Previous Quarter
B
Current Value
B
Quarterly Volatility
830.8 M
 
Yuan Drop
 
Covid
Check Teladoc financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Teladoc's main balance sheet or income statement drivers, such as Depreciation And Amortization of 368.9 M, Interest Expense of 25.1 M or Selling General Administrative of 236 M, as well as many indicators such as Price To Sales Ratio of 1.28, Dividend Yield of 0.0 or PTB Ratio of 1.43. Teladoc financial statements analysis is a perfect complement when working with Teladoc Valuation or Volatility modules.
  
Check out the analysis of Teladoc Correlation against competitors.
For information on how to trade Teladoc Stock refer to our How to Trade Teladoc Stock guide.

Latest Teladoc's Total Liab Growth Pattern

Below is the plot of the Total Liab of Teladoc over the last few years. It is the total amount of all liabilities that a company has, including both short-term and long-term liabilities. Teladoc's Total Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Teladoc's overall financial position and show how it may be relating to other accounts over time.
Total Liab10 Years Trend
Slightly volatile
   Total Liab   
       Timeline  

Teladoc Total Liab Regression Statistics

Arithmetic Mean759,997,653
Geometric Mean163,667,943
Coefficient Of Variation119.32
Mean Deviation804,514,204
Median265,488,000
Standard Deviation906,808,325
Sample Variance822301.3T
Range2.2B
R-Value0.90
Mean Square Error160827.8T
R-Squared0.82
Slope183,434,077
Total Sum of Squares11512218.7T

Teladoc Total Liab History

20242.2 B
20232.1 B
2022B
20211.7 B
20201.9 B
2019588.8 M
2018515.8 M

About Teladoc Financial Statements

Teladoc stakeholders use historical fundamental indicators, such as Teladoc's Total Liab, to determine how well the company is positioned to perform in the future. Although Teladoc investors may analyze each financial statement separately, they are all interrelated. For example, changes in Teladoc's assets and liabilities are reflected in the revenues and expenses on Teladoc's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Teladoc. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Total Liabilities2.1 B2.2 B

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Teladoc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Teladoc's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Teladoc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Teladoc Stock:
Check out the analysis of Teladoc Correlation against competitors.
For information on how to trade Teladoc Stock refer to our How to Trade Teladoc Stock guide.
You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Is Health Care Technology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Teladoc. If investors know Teladoc will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Teladoc listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(5.78)
Revenue Per Share
15.333
Quarterly Revenue Growth
(0.03)
Return On Assets
(0.03)
Return On Equity
(0.52)
The market value of Teladoc is measured differently than its book value, which is the value of Teladoc that is recorded on the company's balance sheet. Investors also form their own opinion of Teladoc's value that differs from its market value or its book value, called intrinsic value, which is Teladoc's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Teladoc's market value can be influenced by many factors that don't directly affect Teladoc's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Teladoc's value and its price as these two are different measures arrived at by different means. Investors typically determine if Teladoc is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Teladoc's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.